Medical Laboratory Testing and Analysis Services (FSS-621-II)

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 established this Master GSA Schedule for medical laboratory testing and analysis services on October 1, 2005, with ordering closed as of September 25, 2023. The vehicle is no longer active; the ordering period has expired nearly three years ago, though task orders awarded under it continue to execute.

The schedule contracts clinical laboratory services across 15 subcategories including clinical chemistry, hematology, cytology, anatomic pathology, immunology, hemostasis, endocrinology, cytogenetics, microbiology, serology, pharmacogenetics, urinalysis, and clinical drugs of abuse testing, along with disease-oriented panels and introduction of new product testing. Recent task orders show the vehicle funding both routine laboratory testing for federal facilities and specialized reference laboratory services, including oncology testing (Oncotype DX), genomic sequencing, lung cancer screening, and prostate cancer diagnostics.

Quest Diagnostics Incorporated dominates the vehicle with 3,112 task orders worth $750.1 million in combined potential value. Laboratory Corporation of America holds 855 orders totaling $525.8 million. These two firms account for roughly 81% of all task orders and 85% of the vehicle's $1.57 billion combined potential value. Arup Laboratories, Sonora Quest Laboratories, and Quest Diagnostics Clinical Laboratories fill secondary positions; 27 distinct primes were awarded across 5,447 total task orders. Competitive concentration is high—the top five primes hold 96% of combined potential value.

The vehicle serves 167 distinct federal customer agencies. The Department of Health and Human Services Indian Health Service, Department of Veterans Affairs regional service networks (particularly VISN 21, 17, 10, and 22), and the Bureau of Prisons drive the largest order volumes. Nearly 91% of awarded task orders carry no set-aside designation; small business awards represent less than one percent of orders.

The vehicle shows sustained recent ordering activity despite the closed ordering period. Task orders awarded in 2026 include routine monthly laboratory testing calls in the $2,000 to $50,000 range and mega-orders for specialized reference laboratory services exceeding $2.5 million. Combined task-order dollars obligated stand at $1.27 billion, representing 81% of combined potential value. The 5,447-order portfolio obligates substantial value across federal healthcare and correctional systems, with performance periods extending through 2027 and beyond.

GeneSight Psychotropic Testing